BioCardia, Inc. (BCDA)

Market Cap	6.97M
Revenue (ttm)	71,000
Net Income (ttm)	-7.72M
Shares Out	3.50M
EPS (ttm)	-3.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,364
Open	2.010
Previous Close	2.030
Day's Range	1.970 - 2.180
52-Week Range	1.840 - 10.950
Beta	1.27
Analysts	Strong Buy
Price Target	25.00 (+1,156.28%)
Earnings Date	Nov 13, 2024

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Peter Altman
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: BCDA
• Website: https://www.biocardia.com

Financial Performance

In 2023, BioCardia's revenue was $477,000, a decrease of -64.72% compared to the previous year's $1.35 million. Losses were -$11.57 million, -2.82% less than in 2022.

Analyst Forecast

According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price forecast is $25.0.

Price Target

$25.0

(1,156.28% upside)

Analyst Consensus: Strong Buy